Clinical trials: sponsored by AbbVie
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
The objective of this study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics (PK ) properties following a single dose of ABBV-277 in healthy adult participants.
- Trial name
- NCT07136103
- Testing
- ABBV-277
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AbbVie
Non-Surgical Fat Reduction
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System
The primary objective of this protocol is the continued collection of data specific to the submental, inner thigh and back/bra body areas with CoolSculpting Elite.
- Trial name
- NCT07122583
- Testing
- CoolSculpting Elite System
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants
The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.
- Trial name
- NCT07466550
- Testing
- Risankizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants
This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.
- Trial name
- NCT06849791
- Testing
- ABBV-932
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants
The objectives for this 2 Part study are to assess the safety, tolerability, and pharmacokinetics following single ascending oral doses of nacresertib in healthy adult participants (Part 1) and to assess the safety, tolerability…
- Trial name
- NCT07566130
- Testing
- nacresertib
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants
The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-1451 after single ascending doses in healthy adult volunteers.
- Trial name
- NCT07570147
- Testing
- ABBV-1451
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants
This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.
- Trial name
- NCT06774313
- Testing
- ABBV-142
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.
- Trial name
- NCT07141199
- Testing
- ABBV-8736
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants
The objective of this study is to evaluate the PK of a tablet formulation of ABBV-722 under fasted conditions and the effect of food on its bioavailability after administration of single doses
- Trial name
- NCT07361367
- Testing
- ABBV-722
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants
The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.
- Trial name
- NCT06895343
- Testing
- ABBV-701
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous administration with an on-body injector relative to a prefilled syringe
- Trial name
- NCT07007091
- Testing
- Risankizumab
- Where
- 4 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers, Overweight
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
This is a two-part, single centre, double-blind (within cohorts), randomised, placebo-controlled, single (Part 1) and multiple (Part 2) ascending subcutaneous dose study in lean to overweight or obese but otherwise healthy men…
- Trial name
- NCT06144684
- Testing
- GUB014295
- Where
- United Kingdom
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants
This is a Phase 1, first in human, randomized, four-part study to investigate the safety, tolerability, and pharmacokinetics of ABBV-CLS-616 after oral dosing in healthy volunteers.
- Trial name
- NCT06698926
- Testing
- ABBV-CLS-616, Itraconazole
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
The objective of this study is to assess the safety, tolerability, pharmacokinetics and immunogenicity of either single ascending intravenous (IV) doses of ABBV-243 or single ascending subcutaneous (SC) doses of ABBV-243 in…
- Trial name
- NCT07306754
- Testing
- ABBV-243
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants
This study is to assess the mass balance of oral ABBV-1354 in healthy adult male participants.
- Trial name
- NCT07219017
- Testing
- ABBV-1354
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants
This study will assess the adverse events, tolerability, and how oral doses of ABBV-932 moves through the body in healthy adult Chinese participants.
- Trial name
- NCT07024797
- Testing
- ABBV-932
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteers
A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants
This study will assess the pharmacokinetics, relative bioavailability, immunogenicity, safety, and tolerability of risankizumab following subcutaneous (SC) administration with a prefilled pen or a prefilled syringe in healthy…
- Trial name
- NCT06946524
- Testing
- Risankizumab
- Where
- 2 sites in United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.
- Trial name
- NCT06937619
- Testing
- Risankizumab
- Where
- 4 sites in United States
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088
This study will assess the safety, tolerability, and pharmacokinetics of ABBV-1088 in healthy adult Western, Han-Chinese and Japanese participants.
- Trial name
- NCT06579300
- Testing
- ABBV-1088, Itraconazole (ITZ)
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AbbVie
Healthy Volunteer
A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants
The objective of this study is to assess the bioavailability (BA) of venetoclax new high drug load hot melt extrusion-03 (HME-03) tablet formulation at two different tablet strengths relative to the commercial venetoclax tablet…
- Trial name
- NCT06742086
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AbbVie